These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

512 related articles for article (PubMed ID: 25739318)

  • 21. The histone methyltransferase EZH2 promotes mammary stem and luminal progenitor cell expansion, metastasis and inhibits estrogen receptor-positive cellular differentiation in a model of basal breast cancer.
    Wu J; Crowe DL
    Oncol Rep; 2015 Jul; 34(1):455-60. PubMed ID: 25998860
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enhancer of zeste homolog 2 is overexpressed and contributes to epigenetic inactivation of p21 and phosphatase and tensin homolog in B-cell acute lymphoblastic leukemia.
    Chen J; Li J; Han Q; Sun Z; Wang J; Wang S; Zhao RC
    Exp Biol Med (Maywood); 2012 Sep; 237(9):1110-6. PubMed ID: 22956625
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhancer of Zeste homolog 2 (EZH2) induces epithelial-mesenchymal transition in endometriosis.
    Zhang Q; Dong P; Liu X; Sakuragi N; Guo SW
    Sci Rep; 2017 Jul; 7(1):6804. PubMed ID: 28754964
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epigenetic regulation of cell adhesion and communication by enhancer of zeste homolog 2 in human endothelial cells.
    Dreger H; Ludwig A; Weller A; Stangl V; Baumann G; Meiners S; Stangl K
    Hypertension; 2012 Nov; 60(5):1176-83. PubMed ID: 22966008
    [TBL] [Abstract][Full Text] [Related]  

  • 25. EZH2 promotes cell migration and invasion but not alters cell proliferation by suppressing E-cadherin, partly through association with MALAT-1 in pancreatic cancer.
    Han T; Jiao F; Hu H; Yuan C; Wang L; Jin ZL; Song WF; Wang LW
    Oncotarget; 2016 Mar; 7(10):11194-207. PubMed ID: 26848980
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structure-Activity Relationship Studies for Enhancer of Zeste Homologue 2 (EZH2) and Enhancer of Zeste Homologue 1 (EZH1) Inhibitors.
    Yang X; Li F; Konze KD; Meslamani J; Ma A; Brown PJ; Zhou MM; Arrowsmith CH; Kaniskan HÜ; Vedadi M; Jin J
    J Med Chem; 2016 Aug; 59(16):7617-33. PubMed ID: 27468126
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activation of the enhancer of zeste homologue 2 gene by the human papillomavirus E7 oncoprotein.
    Holland D; Hoppe-Seyler K; Schuller B; Lohrey C; Maroldt J; Dürst M; Hoppe-Seyler F
    Cancer Res; 2008 Dec; 68(23):9964-72. PubMed ID: 19047178
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutant p53 induces EZH2 expression and promotes epithelial-mesenchymal transition by disrupting p68-Drosha complex assembly and attenuating miR-26a processing.
    Jiang FZ; He YY; Wang HH; Zhang HL; Zhang J; Yan XF; Wang XJ; Che Q; Ke JQ; Chen Z; Tong H; Zhang YL; Wang FY; Li YR; Wan XP
    Oncotarget; 2015 Dec; 6(42):44660-74. PubMed ID: 26587974
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of EZH2 in oral squamous cell carcinoma carcinogenesis.
    Zhao L; Yu Y; Wu J; Bai J; Zhao Y; Li C; Sun W; Wang X
    Gene; 2014 Mar; 537(2):197-202. PubMed ID: 24424512
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Morphological Changes Induced by TKS4 Deficiency Can Be Reversed by EZH2 Inhibition in Colorectal Carcinoma Cells.
    Jacksi M; Schad E; Tantos A
    Biomolecules; 2024 Apr; 14(4):. PubMed ID: 38672463
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Effects of enhancer of zeste homolog (EZH2) downregulation on the proliferation and invasion of nasopharyngeal carcinoma cell and the possible mechanisms].
    LIANG BJ; LI XP; LU J; LIN SX; LIU X; LI G; ZHANG B; WANG L; LUO HN; WAN RQ; TIAN WD
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2012 Apr; 47(4):298-304. PubMed ID: 22800347
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunohistochemical analysis of polycomb group protein expression in advanced gastric cancer.
    Lee H; Yoon SO; Jeong WY; Kim HK; Kim A; Kim BH
    Hum Pathol; 2012 Oct; 43(10):1704-10. PubMed ID: 22520951
    [TBL] [Abstract][Full Text] [Related]  

  • 33. S-Adenosyl-L-methionine-competitive inhibitors of the histone methyltransferase EZH2 induce autophagy and enhance drug sensitivity in cancer cells.
    Liu TP; Lo HL; Wei LS; Hsiao HH; Yang PM
    Anticancer Drugs; 2015 Feb; 26(2):139-47. PubMed ID: 25203626
    [TBL] [Abstract][Full Text] [Related]  

  • 34. EZH2 promotes invasion and metastasis of laryngeal squamous cells carcinoma via epithelial-mesenchymal transition through H3K27me3.
    Luo H; Jiang Y; Ma S; Chang H; Yi C; Cao H; Gao Y; Guo H; Hou J; Yan J; Sheng Y; Ren X
    Biochem Biophys Res Commun; 2016 Oct; 479(2):253-259. PubMed ID: 27638307
    [TBL] [Abstract][Full Text] [Related]  

  • 35. EZH2 is involved in silencing of WNT5A during epithelial-mesenchymal transition of colon cancer cell line.
    Tao J; Shi L; Huang L; Shi H; Chen H; Wang Y; Wang T
    J Cancer Res Clin Oncol; 2017 Nov; 143(11):2211-2219. PubMed ID: 28748258
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity.
    Xu L; Beckebaum S; Iacob S; Wu G; Kaiser GM; Radtke A; Liu C; Kabar I; Schmidt HH; Zhang X; Lu M; Cicinnati VR
    J Hepatol; 2014 Mar; 60(3):590-8. PubMed ID: 24211739
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genome-wide mRNA and miRNA expression profiling reveal multiple regulatory networks in colorectal cancer.
    Vishnubalaji R; Hamam R; Abdulla MH; Mohammed MA; Kassem M; Al-Obeed O; Aldahmash A; Alajez NM
    Cell Death Dis; 2015 Jan; 6(1):e1614. PubMed ID: 25611389
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of Sp1 and EZH2 in the regulation of LMX1A in cervical cancer cells.
    Lin WC; Yan MD; Yu PN; Li HJ; Kuo CC; Hsu CL; Lin YW
    Biochim Biophys Acta; 2013 Dec; 1833(12):3206-3217. PubMed ID: 24018208
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Repression of E-cadherin by the polycomb group protein EZH2 in cancer.
    Cao Q; Yu J; Dhanasekaran SM; Kim JH; Mani RS; Tomlins SA; Mehra R; Laxman B; Cao X; Yu J; Kleer CG; Varambally S; Chinnaiyan AM
    Oncogene; 2008 Dec; 27(58):7274-84. PubMed ID: 18806826
    [TBL] [Abstract][Full Text] [Related]  

  • 40. EZH2 in Bladder Cancer, a Promising Therapeutic Target.
    Martínez-Fernández M; Rubio C; Segovia C; López-Calderón FF; Dueñas M; Paramio JM
    Int J Mol Sci; 2015 Nov; 16(11):27107-32. PubMed ID: 26580594
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.